Company Description
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America.
The company offers its products under the PlusCBD, ProCBD, HappyLane, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers.
It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.
The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016.
CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Joseph D. Dowling |
Contact Details
Address: 9530 Padgett Street, Suite 107 San Diego, California 92126 United States | |
| Phone | 866-290-2157 |
| Website | cvsciences.com |
Stock Details
| Ticker Symbol | CVSI |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001510964 |
| CUSIP Number | 126654102 |
| ISIN Number | US1266541028 |
| Employer ID | 80-0944970 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph D. Dowling | Chief Executive Officer, Secretary and Director |
| Joerg Grasser | Chief Financial Officer |
| Tim Hitchman | Vice President of Operations |
| Jesse Karagianes | Senior Vice President of Revenue Growth |
| Alyssa Dunn | Operations Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Dec 12, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |